ValiRx (LSE:VAL) reported a reduced interim loss and lower administrative expenses for the first half of 2026 as the life sciences company implemented cost reductions and refocused its development portfolio.
The company said its lean operating strategy was fully implemented during the period, reducing administrative costs and generating additional annual savings. ValiRx also repositioned Inaphaea BioLabs to focus more closely on supporting its internal development pipeline, alongside the introduction of a stricter process for selecting assets.
Cash at the end of the period stood at £970,564, more than double the prior-year level. The balance was supported by a £1.155 million fundraising completed in June at an issue price of 0.2 pence per share.
ValiRx Advances Development Portfolio
During the period, ValiRx took further evaluation and licensing steps relating to an oral RNA helicase inhibitor and progressed intellectual property work covering formulations of oncolytic peptides.
The company also reported progress on its Digital Twin collaboration and continued expanding its biobank and academic partnerships.
ValiRx established an animal health subsidiary and secured a European patent covering its Cytolytix nanoparticle technology. The company is also evaluating the potential commercialisation of anonymised datasets for artificial intelligence applications.
Management is seeking to develop additional revenue sources and use a combination of dilutive and non-dilutive funding to support the company’s activities.
ValiRx Operations
ValiRx is a London-listed life sciences company focused on early-stage cancer therapeutics and women’s health. Its operations include Inaphaea BioLabs and the newly established ValiRx Animal Health subsidiary.
The company uses internal and partnered research capabilities to develop pre-clinical drug candidates, with its business model including the potential out-licensing of selected assets for further clinical development and commercialisation.
Leave a Reply